Jennifer N. Uram, Ph.D.
Affiliations: | 2009 | Johns Hopkins University, Baltimore, MD |
Area:
Immunology, OncologyGoogle:
"Jennifer Uram"Parents
Sign in to add mentor| Elizabeth M. Jaffee | grad student | 2009 | Johns Hopkins | |
| (Non-dominant CD8 T cell repertoire: Active players or bystanders in anti-tumor immunity?) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Le DT, Crocenzi TS, Uram JN, et al. (2016) Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). Journal of Clinical Oncology. 34: TPS486-TPS486 |
| Le DT, Uram JN, Wang H, et al. (2016) PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. Journal of Clinical Oncology. 34: 195-195 |
| Diaz LA, Uram JN, Wang H, et al. (2016) Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology. Journal of Clinical Oncology. 34: 3003-3003 |
| Le DT, Uram JN, Wang H, et al. (2016) Programmed death-1 blockade in mismatch repair deficient colorectal cancer. Journal of Clinical Oncology. 34: 103-103 |
| Le DT, Uram JN, Wang H, et al. (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England Journal of Medicine. 372: 2509-20 |
| Le DT, Wang-Gillam A, Picozzi V, et al. (2015) Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1325-33 |
| De Remigis A, de Gruijl TD, Uram JN, et al. (2015) Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. International Journal of Cancer. 136: 127-37 |
| Wang JS, Gootjes EC, Uram JN, et al. (2015) A phase I study of investigational agent SGI-110 combined with irinotecan in previously treated metastatic colorectal cancer patients. Journal of Clinical Oncology. 33 |
| Chen G, Gupta R, Petrik S, et al. (2014) A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunology Research. 2: 949-61 |
| Zheng L, Edil BH, Soares KC, et al. (2014) A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer. Annals of Surgical Oncology. 21: 3931-7 |